Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.46 |
| ▸ | ACACB | O00763 | 6/20 | 0.41 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | OXTR | P30559 | 1/20 | 0.39 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KRAS | P01116 | 1/20 | 0.36 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.36 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1280129 | 0.84 | GPR119 (0.56) | GPR119RETMEN1KMT2A | |
| SCHEMBL23763271 | 0.81 | GPR119 (0.43) | GPR119ACACBCYP11B2SCD5 | |
| SCHEMBL5427926 | 0.80 | CKS1B (0.53) | GPR119MEN1KMT2A | |
| SCHEMBL14780105 | 0.80 | CYP11B2 (0.47) | GPR119ACACBEIF2AK4RETEGLN2 | |
| SCHEMBL3486596 | 0.79 | GPR119 (0.72) | GPR119 | |
| SCHEMBL22470063 | 0.78 | KMT2A (0.43) | GPR119EIF2AK4RETEGLN2CYP11B2 | |
| SCHEMBL30327758 | 0.76 | CYP11B2 (0.45) | ACACBEIF2AK4RETCYP11B2PARP1 | |
| SCHEMBL20510354 | 0.76 | EGLN2 (0.49) | GPR119ACACBRETEGLN2CYP11B2 | |
| SCHEMBL20469052 | 0.76 | CYP11B2 (0.51) | GPR119ACACBRETCYP11B2SCD5 | |
| SCHEMBL30327616 | 0.76 | CYP11B2 (0.46) | GPR119ACACBEIF2AK4CYP11B2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3694330-B1 | INDAZOLYL-SPIRO[2.2]PENTANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-04-19 | — | — | EP | disclosed |
| US-11161854-B2 | Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20210188863-A1 | INDAZOLYL-SPIRO[2.2]PENTANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | US | disclosed |
| EP-3694330-A1 | INDAZOLYL-SPIRO[2.2]PENTANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Merck Sharp & Dohme Corp. (US) | 2020-08-19 | — | — | EP | disclosed |
| WO-2019074809-A1 | INDAZOLYL-SPIRO[2.2]PENTANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2019-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11161854-B2 | Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | LRRK2, GRK2, CLK2 | GPR119 658/4885ACACB 3404/4885EIF2AK4 66/4885 |
| US-20210188863-A1 | INDAZOLYL-SPIRO[2.2]PENTANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LRRK2, GRK2, CLK2 | GPR119 658/4885ACACB 3404/4885EIF2AK4 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.